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Abstract
Introduction—Impaired endothelial function, as assessed by brachial artery flow-mediated 
dilation (FMD), is an established risk factor for cardiovascular events. FMD is impaired in heart 
failure (HF) patients, but less is known about hyperemic brachial artery flow. We investigated the 
relationship between FMD and hyperemic flow with adverse clinical outcomes in HF patients.
Methods—Brachial artery FMD and hyperemic flow were assessed in 156 patients (70.5 % 
Male; 45.5% Caucasian; mean age (± SD) = 56.2 (± 12.4) years) with HF and reduced left 
ventricular ejection fraction (LVEF). Cox proportional hazard models were used to assess the 
potential explanatory association of FMD and hyperemic flow with the composite outcome of 
death or cardiovascular hospitalization over a median 5-year follow-up period.
Results—Both FMD and hyperemic flow were negatively correlated with age, but unrelated to 
sex, race, body mass index, LVEF or N-terminal pro-B-Type natriuretic peptide (NT-ProBNP). 
Reduced hyperemic flow, but not FMD, was associated with an increased risk of death or cardiac 
hospitalization after controlling for traditional risk factors.
Conclusion—The association of reduced hyperemic flow with increased risk of adverse clinical 
outcomes suggests that micro-vascular function may be an important prognostic marker in patients 
with HF.
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INTRODUCTION
Nearly 6 million Americans suffer from heart failure (HF) (1) with a 46% increase projected 
by 2030 (2). Both the instability of symptoms and deterioration of patients’ clinical status 
can lead to hospitalization for HF, which is estimated to result in an annual cost of $31 
billion (1). The vascular endothelium plays an important role in the regulation of vascular 
tone, coagulation, cell adhesion, and cell proliferation, and endothelial dysfunction is a 
predictor of atherosclerotic events (3–5). Flow-mediated dilation (FMD) of the brachial 
artery is a useful non-invasive measure of endothelial function that is considered broadly 
reflective of the endothelial health of the entire arterial system, including the coronary 
arteries (6).
Endothelial dysfunction is linked to a wide range of cardiovascular risk factors (7–9) and is a 
predictor of cardiovascular events, independent of other traditional risk factors (4,10,11). 
Endothelial dysfunction is evident in HF patients (12–14), and previous studies have 
suggested that impaired FMD is predictive of cardiac death and hospitalization (12,13,15). 
The stimulus for the FMD response is increased shear stress, which is evoked by transient 
forearm occlusion giving rise to hyperemic flow through the brachial artery. There is some 
evidence that cardiovascular risk is related to hyperemic velocity (14,16), with some studies 
noting that the hyperemic response to forearm ischemia is a better predictor of adverse 
cardiovascular outcomes than FMD (17,18).
Although comparatively few studies have examined the relationship between FMD and 
clinical events in patients with HF, they have shown that impaired FMD is associated with 
worse clinical outcomes (12,13,15,19,20). However, none of these studies assessed the 
potential role of hyperemic flow as an independent predictor of adverse outcomes. 
Therefore, we evaluated whether FMD and reactive hyperemia were associated with risk of 
death or cardiac hospitalization in patients with HF, in a secondary analysis from a 
previously reported study (21) .
MATERIAL AND METHODS
Participants
Participants were recruited from a series of patients seen at the heart failure clinics at Duke 
University Medical Center and the University of North Carolina at Chapel Hill, from 
January 2000 through December 2002. Approximately 500 patients that met our eligibility 
criteria (see below) were approached; 219 of these patients consented to participate and were 
enrolled; for 204 of these participants we obtained a plasma NT-proBNP value necessary to 
control for HF disease severity in our analyses, as reported in our original paper (21). From 
this main sample, 156 of these participants were NOT taking nitrates and were included in 
the current analyses; no participants were lost to clinical follow-up which included 156 of 
the participants comprising the current sample (N=156). Inclusion criteria were: New York 
Heart Association class II-III HF; chronic HF of at least 3-months duration; and left 
ventricular ejection fraction (LVEF) of 40% or less as assessed by echocardiography, 
radionuclide imaging, or left ventriculography within 6 months of study enrollment. 
Exclusion criteria were: uncontrolled hypertension (blood pressure (BP) > 180/105 mm Hg); 
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myocardial infarction or coronary revascularization procedure in the past 3 months; HF due 
to correctable cause or condition, such as uncorrected primary valvular disease, uncorrected 
thyroid heart disease, or persistent tachyarrhythmia; pacemaker dependence; use of 
mechanical assist devices; life limiting or complicated illness including cancer, renal 
dysfunction, hepatic dysfunction, dementia, and nitrate use. Patients who were pregnant, had 
atrial fibrillation, reported alcohol or drug abuse within 12 months, or were unable to 
comply with the assessment procedure or to provide informed consent were excluded. The 
study complies with the Declaration of Helskinki and was approved locally by the 
Institutional Review Board at Duke University Medical Center, where all assessments were 
performed. Written informed consent was obtained from all participants before their 
participation.
Assessments
Clinical Status and Medications—Heart failure diagnosis, etiology, comorbidities and 
health behaviors (smoking, alcohol use) were assessed by questionnaires and medical record 
review. Medication use was documented by participants showing research staff all their 
current medications. Blood samples for NT-proBNP analysis were taken, stored and 
analyzed in line with standard procedures and with the associated coefficients as described 
elsewhere (22).
Blood Pressure—BP was assessed using a Suntech 4240 blood pressure monitor, with 
measurements of systolic (SBP) and diastolic (DBP) BP acquired during the final 5 minutes 
of a 30 minute period of quiet relaxation in a seated posture.
Endothelial Function—All participants completed the FMD assessment protocol in the 
morning, following an overnight fast. Prescribed medications were taken as normal, except 
for low dose aspirin which participants took with a breakfast provided following the FMD 
assessment protocol. While others advise that if possible, vasoactive medications should be 
withheld prior to FMD assessment (23), the maintenance of the medication regimen in this 
study allows us to ascertain the predictive value of FMD and reactive hyperemia on 
outcomes, when taking these daily medication regimens, leading us to more generalizable 
data relevant to our population. Vascular imaging was performed by a single sonographer 
using an Acuson Aspen ultrasound platform equipped with an Acuson L10 (7–10 MHz) 
linear array transducer, following guidelines described elsewhere (23). After the participant 
had rested for 10 min in the supine posture, longitudinal B-mode images of the brachial 
artery, in the region 4 to 6 cm proximal to the antecubital fossa, were acquired. Images were 
then captured during the first 120 seconds of reactive hyperemia achieved by inflation of a 
pneumatic occlusion cuff located around the forearm to supra-systolic pressure (~200 mm 
Hg) for 5 minutes. Gated end-diastolic images of the artery were stored and arterial 
diameters were measured as the distance between the proximal and distal arterial wall 
intima-media interfaces using PC-based software (Brachial Analyzer - Version 5.0, Medical 
Imaging Applications LLC, Iowa City, Iowa). Peak FMD response was assessed from 10–
120 seconds post-deflation of the cuff, with peak arterial diameter quantified using 
polynomial curve fitting. FMD was expressed as percent increase in arterial diameter 
(maximum arterial diameter - baseline arterial diameter/baseline arterial diameter × 100) 
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(23). Because the percent change index may result in bias towards greater vasodilation in 
smaller arteries (23), baseline arterial diameter was used as a covariate in all analyses. 
Pulsed Doppler flow signals in the brachial artery were recorded at baseline and for up to 15 
seconds after cuff release. The velocity-time integral for baseline and reactive hyperemia 
was based upon the mean of triplicate pulsed-Doppler flow tracings recorded at each of 
these phases. Hyperemic velocity was derived by dividing the velocity-time integral by the 
inter-beat interval, and hyperemic flow was calculated from hyperemic velocity and brachial 
artery cross-sectional area. All ultrasound image analyses were performed blinded to 
participants’ identities. In our previous work, we have demonstrated excellent 
reproducibility of the FMD measure (r=0.81) between participants (24).
Follow-up of vital status and hospitalizations—The medical records of participants 
were reviewed annually, on the anniversary of their baseline assessments, over a median of 5 
years (with a range of 4 to 7 years); no participants were lost to follow-up. Each year, 
patients also were contacted by mail and asked to indicate whether they had been 
hospitalized during the previous 12 months and provided consent for retrieval of their 
hospitalization records. The primary end point was defined as the time to cardiovascular 
hospitalization or death (whichever occurred first) within the follow-up period. Death and 
instances of cardiac hospitalization were verified through hospital and emergency medical 
services records and reviewed at semi-annual cause-of-death (COD) committee meetings, 
whereby COD will be established by consensus. Any hospitalization for myocardial 
infarction, stroke, worsening HF, coronary artery bypass graft surgery, or heart 
transplantation was classified as a cardiovascular hospitalization and confirmed by 
consensus.
Data Analysis—Results are presented as means with standard deviations (SD) or 
percentages (%) where appropriate. Participants who were taking nitrates were excluded, 
given the role of nitrates in vasodilation and regulation of vascular tone; thus, 156 
participants were included in the final analyses. Pearson’s correlations were utilized to 
determine the univariate relationships between FMD and hyperemic flow with age, sex, race, 
BMI, LVEF, and N-terminal pro-brain natriuretic peptide (NT-ProBNP).
Cox proportional hazards regression (PHREG) models were used to assess the associations 
of FMD and hyperemic flow with death or cardiac hospitalization over a 5 year follow up 
period. In the PHREG models to evaluate the potential explanatory roles of FMD and 
hyperemic flow, HF etiology (ischemic or nonischemic), LVEF, NT-ProBNP, age, and 
baseline heart rate (HR) were included in planned models. In order to account for individual 
differences in vessel diameter, baseline arterial diameter was included in all models. NT-
proBNP was expressed as NT-proBNP/1000 and age was expressed as age/10. As a further 
conservative strategy to confirm the adequacy of the planned models, other possibly relevant 
factors related to outcome were made available for inclusion in the model by stepwise 
selection (significance level required for entry into the model was ≤ p 0.10). These factors 
included current alcohol use, current smoking status, defibrillator, diabetes, hypertension, 
hypercholesterolemia, estimated GFR, as well as usage of the following medication classes: 
anti-platelet drugs, beta blockers, anti-coagulants, antidepressants, statins, diuretics, ACE-
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inhibitors and ARBs. All statistical analyses were conducted using the SAS 9.3 system (SAS 
Institute, Cary, NC) with significance set at p = .05.
RESULTS
Demographic and clinical characteristics of the study sample are summarized in Table 1. Out 
of the 156 participants in our study, 122 experienced death or a cardiac event (78.2%), with 
62 participants dying during our 5 year follow-up (39.7%). The mean FMD (±SD) in our HF 
population was 4.6 ± 3.4%, and mean reactive hyperemic flow was 0.87 ± 0.42 L/min. 
Across our sample, 35% had ischemic etiology, an average LVEF of 31%, nearly 10% had a 
pacemaker and nearly 6% had an ICD. Regarding medication use, our sample were taking 
beta-blockers (85%), diuretics (90%), ACE inhibitors (89%), statins (40%), anti-coagulants 
(30%) and antidepressants (nearly 20%). Age was correlated with both FMD (r (155) = 
−0.24, p = 0.003) and hyperemic flow (r (155) = −0.36, p < 0.001). No significant 
associations were observed between FMD or hyperemic flow and other demographic or 
clinical characteristics.
Cox Proportional Hazards Regression Models
Unadjusted Cox proportional hazards regression models were performed to examine the 
relationships of vascular function (i.e., FMD and hyperemic flow) to death or cardiac 
hospitalization. In models which also included HF etiology, LVEF, NT-ProBNP, age, 
baseline HR, and baseline arterial diameter, hyperemic flow was predictive of death or 
cardiac hospitalization (HR=0.931; 95% CI 0.873–0.993; p = 0.030) whereas FMD was not 
predictive (HR=1.048; 95% CI 0.981–1.118; p = 0.17). Inclusion of both in the model (Table 
2), revealed hyperemic flow to still be predictive of death of cardiac hospitalization 
(HR=0.923; 95% CI 0.867–0.983; p = 0.013), whereas FMD was not (HR=1.046; 95% CI 
0.980–1.117; p = 0.17). In the extended model, hypercholesterolemia was also included by 
stepwise selection, but the explanatory roles of FMD (HR=1.062; 95% CI 0.993–1.135; p = 
0.08) and hyperemic flow (HR=0.935; 95% CI 0.878–0.997; p = 0.04) remained unchanged, 
indicating that the planned model was robust. Additional analyses which included all 
participant characteristics in the extended model did not change the pattern of the results.
Kaplan Meier survival curves illustrating the relationship between hyperemic flow and 
clinical events are shown in Figure 1, using tertiles of hyperemic flow (High hyperemic flow 
= flow greater than 0.975 L/min; Intermediate hyperemic flow = less than 0.975 L/min but 
greater than 0.64 L/min; Low hyperemic flow = flow less than 0.64 L/min). Using the lowest 
tertile group (i.e., lowest hyperemic flow response) as a reference point, individuals in the 
highest tertile group (i.e., with the largest reactive hyperemic flow response) had a reduced 
risk of death or cardiac hospitalization (HR, 0.531; 95% CI 0.278–1.017; p = 0.056); risk for 
individuals in the intermediate tertile was comparable to those in the lowest tertile (HR, 
1.016; 95% CI 0.618–1.672; p = 0.95).
DISCUSSION
The current study assessed the associations of FMD and reactive hyperemic flow with death 
or cardiac hospitalization in heart failure patients with reduced LVEF. Reduced reactive 
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hyperemic flow following forearm occlusion was associated with these adverse outcomes 
over a follow up period of 5 years, but FMD was not. HF patients with the greatest 
hyperemic flow were at lowest risk. Our findings are similar to those of Huang et al., who 
found that reduced reactive hyperemic velocity was predictive of death or cardiac 
hospitalization in patients with peripheral arterial disease (18). Anderson and colleagues also 
found that reactive hyperemia was indicative of cardiovascular risk in healthy individuals 
(17).
In contrast to previous studies, we did not find FMD to be an independent predictor of 
cardiac death or hospitalization in HF patients (12,13,15,19). Because our study sample was 
larger than the majority of previous studies, it is unlikely that our null finding for impaired 
FMD as a risk factor for adverse outcomes in HF could be attributed to lack of statistical 
power. Indeed, in marked contrast to prior studies, when controlling for hyperemic flow and 
background characteristics, there was a non-significant trend for a greater FMD response to 
be associated with worse clinical outcomes. One possible explanation for the discrepancy is 
that participants in our study were more likely to be taking beta-blockers than in the 
previously reported studies; 85% of our sample was on beta blockers.
Alternatively, over 60% of patients in our study sample were taking statins, which is higher 
than the levels observed in the study reported by Huang et al.(18). However, in a similar 
study reported by Calderaro et al (25), 98% of their high risk vascular patients were taking 
statins, and hyperemic flow and not FMD was found to be associated with worse clinical 
outcomes. Given the pleiotropic effects of statins on endothelial function (26,27), higher 
statin use may promote better endothelial function and thereby possibly negate the potential 
of FMD (a reflection of endothelial function) to predict risk of death or events in these types 
of patients. This may be particularly important considering that beta-blockade use enhances 
the pleiotropic effects of statins on endothelial function (28), and our sample reported a very 
high use of beta-blockers (85%). Additionally, only Katz et al. (19) asked participants to 
discontinue nitrate use on the morning of the vascular assessment, whereas the other studies 
did not appear to control for nitrate use. Given that acute administration of nitrates causes 
vasodilation, whereas chronic administration can lead to endothelial dysfunction (29,30), the 
use of nitrates may have been a confounding factor in some of the previous studies. 
Alternatively, our discrepant findings might imply that impaired microvascular function may 
be more important as a marker of vascular disease and associated risk than the assessment of 
FMD in a conduit artery (31), given that hyperemic flow is secondary to vasodilation in 
microvascular beds.
Hyperemic flow and accompanying shear stress is the stimulus for FMD, with hyperemic 
velocity often associated with other traditional cardiovascular disease (CVD) risk factors 
(14,16). In the Framingham study, reactive hyperemia demonstrated more robust 
associations with traditional CVD risk factors and hyperemic sheer stress than FMD (16,32). 
Statistical adjustment for hyperemic velocity reduced the strength of the observed 
associations between FMD and CVD risk factors, further supporting the potential value of 
hyperemic flow as a marker of risk for CVD events (16). Attenuated hyperemic flow in the 
coronary circulation can lead to a worsening of myocardial ischemia, and may be a 
triggering factor for cardiac events (18). Coronary microvascular function has been linked to 
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adverse CVD outcomes in coronary artery disease patients (33,34), with reduced hyperemic 
flow or microvascular dysfunction associated with increasing risk of cardiovascular events, 
as well as the development of HF (35).
Limitations and methodological considerations
With assessment of brachial artery hyperemic responses and FMD, methodological 
considerations must be discussed. Firstly, FMD has been criticized as a user-dependent 
measurement in contrast to reactive hyperemia, and should be considered when interpreting 
FMD results (36). As noted elsewhere, upper arm occlusion is technically challenging for 
accurate data acquisition as the image can be distorted by collapse of the brachial artery 
(23), however, forearm occlusion was completed in the current study and we observed no 
arterial collapse at the imaging site. Further, changes in FMD of the conduit artery could be 
interpreted as changes in flow (indirectly as a consequence of changes in the 
microcirculation) rather than endothelial function improvements (23). Thus, as 
recommended by guidelines (23), our reporting of hyperemic flow should help to determine 
that our assessment of FMD was not indicative of flow. Finally, while statistical adjustments 
were made as a part of our analyses, it should be clarified that this cannot account for 
biological processes. Although our analyses did not show any differences in FMD or 
hyperemic flow associated with BMI, nor any predictive value of BMI on risk of death or 
cardiac hospitalization, future work should nonetheless consider the potential effects of 
obesity on reactive hyperemia and its relationship to clinical outcomes. Better assessments 
of obesity, including waist circumference, lipid profiles and body composition may prove to 
be more informative.
In summary, our study of stable HF outpatients with reduced ejection fraction showed that 
reactive hyperemic blood flow, but not brachial artery FMD, was associated with adverse 
clinical outcomes. Compared with a strong reactive hyperemic response, moderately or 
markedly reduced reactive hyperemia were associated with significantly greater risk of 
hospitalization or death over 5 years of follow-up. These findings are consistent with 
growing evidence that peripheral microvascular dysfunction may be an important marker of 
risk for adverse cardiovascular outcomes in patients with coronary artery disease (CAD) and 
HF.
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ABBREVIATIONS
HF Heart Failure
FMD Flow Mediated Dilation
LVEF Left Ventricular Ejection Fraction
BP Blood Pressure
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SBP Systolic Blood Pressure
DBP Diastolic Blood Pressure
COD Cause of Death
BMI Body Mass Index
NT-ProBNP N-terminal pro-Brain Natriuretic Peptide
HR Heart Rate
GFR Glomerular Filtration Rate
ACE Angiotensin Converting Enzyme
ARB Angiotensin II Receptor Blockers
CVD Cardiovascular Disease
CAD Coronary Artery Disease
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Figure 1. 
Kaplan Meier survival curves which illustrate the associated risk between death or cardiac 
hospitalization and hyperemic flow responses. Note: High hyperemic flow = flow greater 
than 0.975 L/min; Intermediate hyperemic flow = less than 0.975 L/min but greater than 
0.64 L/min; Low hyperemic flow = flow less than 0.64 L/min
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Table 2
Cox proportional hazard regression analyses in relation to the composite outcome of death or cardiac 
hospitalization
Variable Planned Model
*
 Hazard Ratio (95% 
CI) P Value
Extended Model† Hazard Ratio (95% 
CI) P Value
Etiology 1.773 (1.151–2.730) 0.009 2.167 (1.343–3.496) 0.002
LVEF 0.973 (0.953–0.993) 0.009 0.972 (0.953–0.992) 0.006
NT-ProBNP 1.234 (1.114–1.368) <0.0001 1.227 (1.107–1.360) <0.0001
Age 0.914 (0.756–1.103) 0.35 0.920 (0.764–1.107) 0.38
Baseline HR 1.020 (1.000–1.039) 0.047 1.020 (1.001–1.040) 0.040
Baseline Arterial Diameter 1.232 (0.903–1.680) 0.19 1.284 (0.931–1.171) 0.13
FMD 1.046 (0.980–1.117) 0.17 1.062 (0.993–1.135) 0.08
Hyperemic Flow 0.923 (0.867–0.983) 0.013 0.912 (0.854–0.973) 0.0055
Hyperlipidemia - - 1.528 (0.963–2.426) 0.07
Note: CI = confidence interval; LVEF = left ventricular ejection fraction; NT Pro-BNP = N-terminal pro-natriuretic peptide; HR = heart rate; FMD 
= flow-mediated dilation. NT-proBNP was expressed as NT-proBNP/1000, age was expressed as age/10 and hyperemic flow was expressed as 
hyperemic flow/1000.
*Adjusted for etiology, LVEF, NT-ProBNP, age, baseline HR, baseline arterial diameter, hyperemic flow and FMD.
†Adjusted for the variables in the a priori planned model, as well as hyperlipidemia
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